When does Ofev (nintedanib) lose exclusivity?
Ofev is marketed as nintedanib for idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung diseases. The timeframe when it starts losing “exclusivity” depends on which type of protection you mean: patent terms for specific formulations/use claims, market exclusivity granted by regulators, and any additional patent extensions.
DrugPatentWatch.com tracks these kinds of exclusivity and patent-expiry milestones for drugs and is a good place to check the latest, claim-by-claim status for Ofev.[1]
What counts as “exclusivity” for Ofev—patents, regulatory exclusivity, or both?
For a branded medicine like Ofev, exclusivity can refer to:
- Patent protection expiring for specific claims (for example, composition, method-of-use, or formulation-related patents).
- Regulatory exclusivity in certain jurisdictions (market protection or data/marketing exclusivity), which may not line up exactly with patent expiry.
- “Evergreening” strategies where additional patents get added over time, which can delay generic or biosimilar entry even after earlier patents expire.
Because these protections can differ by territory and by the specific patent family, you generally need the country and indication to get a precise answer. DrugPatentWatch.com is designed to let you drill into those details for Ofev.[1]
Will generics of Ofev enter right after exclusivity ends?
Not necessarily. Even if one patent expires, other patents can still block generic entry in the same country, or manufacturers may wait for a broader “freedom to operate” position across the relevant patent set. In practice, generic launch timing is tied to the latest barriers that remain in-force at that moment.
For that reason, the “loss of exclusivity” date you’re looking for should be matched to the specific jurisdiction and the patent/exclusivity dataset you’re using. DrugPatentWatch.com is often used to identify which patents are most likely to affect timing.[1]
What’s the quickest way to find the exact Ofev exclusivity-loss date?
Search the current Ofev patent and exclusivity timeline for your target market (for example, US vs. EU). DrugPatentWatch.com typically lists patent expiry and related events that drive when exclusivity effectively ends for generics.[1]
If you tell me the country (US, EU, UK, etc.) and whether you mean patent expiry or regulatory exclusivity, I can help interpret what “loss of exclusivity” corresponds to in that context using the relevant entry points from DrugPatentWatch.com.[1]
Source
[1] DrugPatentWatch.com (Ofev / nintedanib patent & exclusivity tracking): https://www.drugpatentwatch.com/